Advertisement

Journal of Bone and Mineral Metabolism

, Volume 33, Issue 3, pp 355–358 | Cite as

Atypical femoral fracture in a patient treated with denosumab

  • Kareeann Sok Fun Khow
  • Tuck Yean Yong
Case Report

Abstract

Atypical fractures of the femur (AFF) have been reported in the literature at an increasing rate over the past decade, especially in patients who have been on prolonged courses of bisphosphonates. However, there have only been a few reported cases of AFF in those treated with other antiresorptive medications. In this case report, a 72-year-old woman with chronic obstructive pulmonary disease and osteoporosis presented with an atraumatic right femoral fracture in the setting of denosumab use. In contrast with other reports, this patient had received bisphosphonate therapy for a short duration before the switch to denosumab. While causality between the fracture and denosumab use cannot be established in this case, there is a growing number of reports of a similar association. Ongoing vigilance is required to determine whether denosumab is associated with or potentially a cause of AFF.

Keywords

Atypical femoral fractures Denosumab Osteoporosis 

Notes

Conflict of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Giannini S, Chiarello E, Tedesco G, Cadossi M, Luciani D, Mazzotti A, Donati DM (2013) Atypical femoral fractures. Clin Cases Miner Bone Metab 10:30–33PubMedCentralPubMedGoogle Scholar
  2. 2.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMedGoogle Scholar
  3. 3.
    Diab DL, Watts NB (2014) Denosumab in osteoporosis. Expert Opin Drug Saf 13:247–253CrossRefPubMedGoogle Scholar
  4. 4.
    Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4492CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Paparodis R, Buehring B, Pelley EM, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19:e64–e68CrossRefPubMedGoogle Scholar
  6. 6.
    Thompson RN, Armstrong CL, Heyburn G (2013) Bilateral atypical femoral fractures in a patient prescribed denosumab--A case report. Bone 61C:44–47Google Scholar
  7. 7.
    Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL (2013) An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol 2013:249872PubMedCentralPubMedGoogle Scholar
  8. 8.
    Drampalos E, Skarpas G, Barbounakis N, Michos I (2014) Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop 85:3–5CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Schilcher J, Aspenberg P (2014) Atypical fracture of the femur in a patient using denosumab--a case report. Acta Orthop 85:6–7CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMedGoogle Scholar
  11. 11.
    Denosumab 60 mg: rare cases of atypical femoral fracture with long-term use. MHRA Drug Safety Update 2013 Volume 6, Issue 7. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON2394 (accessed 1/4/2014)
  12. 12.
  13. 13.
    FDA Adverse Event Reporting System (FAERS): latest quarterly data files. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. [accessed 1/4/2014]
  14. 14.
    Li J, Miller MA, Hutchins GD, Burr DB (2005) Imaging bone microdamage in vivo with positron emission tomography. Bone 37:819–824CrossRefPubMedGoogle Scholar
  15. 15.
    Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061CrossRefPubMedGoogle Scholar
  16. 16.
    Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55:495–500CrossRefPubMedGoogle Scholar
  17. 17.
    Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Aged and Extended CareThe Queen Elizabeth Hospital and University of AdelaideAdelaideAustralia
  2. 2.Flinders Private HospitalAdelaideAustralia

Personalised recommendations